UK PM Keir Starmer defends Chancellor Rachel Reeves | BBC Newscast

Key Concepts

• Office for Budget Responsibility (OBR): An independent public body that provides independent analysis of the UK's public finances.
• Economic and Fiscal Outlook (EFO): The OBR's flagship publication, providing forecasts for the UK economy and public finances.
• Operational Resilience: The ability of an organization to prevent, respond to, recover from, and learn from operational disruptions.
• Market Sensitive Information: Data that, if released prematurely, could significantly impact financial markets.
• Productivity Growth: A measure of the efficiency of an economy, reflecting the output per unit of input.
• Fiscal Rules: Government-imposed limits on public spending, borrowing, and debt.
• Headroom: The buffer or margin of safety within fiscal rules.
• Tax Receipts: The revenue collected by the government from taxes.
• NICE (National Institute for Health and Care Excellence): The UK body that appraises new medicines and treatments for the NHS.
• Quality-Adjusted Life Year (QALY): A measure of the benefit of a health intervention, combining quantity and quality of life.
• Rebate: A discount or refund given to a buyer, in this case, the NHS receiving rebates from pharmaceutical companies.
• Most Favored Nation (MFN) Declaration: A trade policy principle where a country agrees to grant the same trade privileges to all other countries with which it has MFN status.

OBR Resignation and Data Breach

The episode begins with the unexpected resignation of Richard Hughes, the head of the Office for Budget Responsibility (OBR), just hours before the recording. This resignation stems from an "operational resilience" issue rather than a fiscal judgment error. The OBR's Economic and Fiscal Outlook (EFO), considered the "bible" for understanding the budget's implications, was made accessible on their website over 40 times before the Chancellor's speech in the House of Commons.

Key Points:

• Nature of the Incident: The OBR report was accessible due to a system vulnerability, specifically related to the use of WordPress software. Documents uploaded to the website were not properly secured, allowing individuals to guess web addresses and access them.
• Historical Precedent: This was not the first instance of such an issue; a similar event occurred in March.
• Severity: The OBR described this as the "worst episode in its history."
• Impact: The premature release of market-sensitive data raises questions about potential insider trading and the integrity of the budget process.
• OBR's Structure: The OBR is an independent watchdog with a relatively small budget (a few million pounds) and around 52 staff, operating with a mentality of a small organization. Its autonomy, using its own website rather than gov.uk, is highlighted.
• Richard Hughes' Tenure: He had been in post for five years and had his term renewed, indicating his resignation was a significant event.

Allegations of Misleading the Public

The discussion shifts to concerns raised by Chris Mason regarding whether the Chancellor, Rachel Reeves, misled the public in the lead-up to the budget. Mason argues that while Reeves did not state anything factually incorrect, she failed to provide a "whole truth" by omitting crucial information.

Key Arguments and Evidence:

• Chancellor's Pre-Budget Conference: Reeves held an unprecedented voluntary news conference a month before the budget to "pitch roll" or prepare the public for what was to come.
• Focus on Productivity Downgrade: Reeves heavily emphasized a significant downgrade in productivity growth forecasts from the OBR, which implied a £16 billion worsening in public finances. This painted a bleak picture of the economic situation.
• Omission of Tax Receipt Improvement: Crucially, Reeves did not mention a simultaneous improvement in tax receipts, largely due to higher-than-expected inflation and wage growth. This improvement offset the productivity downgrade, a fact known to the government and OBR in October.
• Chris Mason's Judgment: Mason, after reviewing briefings and statements, concluded that the public was misled by the selective presentation of information. He likens the situation to a lawyer offering "the truth, the whole truth, and nothing but the truth," implying the Chancellor fell short of the latter two.
• Prime Minister's Response: The Prime Minister acknowledged that the government was contemplating breaching manifesto commitments on income tax rates due to the difficult fiscal situation. He defended the government's actions by stating that the productivity downgrade made the situation "tricky" and that they ultimately found alternatives to manifesto breaches. He argued that the overall process saw numbers improve and that they were not misleading.
• Economic Community's Puzzlement: The economics community was puzzled by the government's initial focus on the negative productivity figures without acknowledging the positive tax receipt data.
• Financial Times Report: A leak to the Financial Times ten days after the Chancellor's conference revealed that income tax rates would not be changed, prompting the government to then cite improved tax receipts as a reason for this decision, a justification they had not used previously.

Supporting Evidence:

• The OBR's letter on Friday (prior to the budget) specified the balancing effect of the productivity downgrade and the tax receipt upgrade.
• The Chancellor's speech from the beginning of November heavily leaned on productivity but made no mention of the increase in tax receipts.
• The Prime Minister's public acknowledgment of contemplating manifesto breaches.

Economic and Political Consequences

The discussion explores the broader implications of these events.

Economic Consequences:

• Uncertainty and Transparency: The "twists and turns" and the need for transparency created uncertainty, described as feeling like "pieces of fusili."
• Impact on Investment and Spending: Economists are concerned that this uncertainty may have negatively impacted business investment, job creation, and consumer spending, potentially leading to decisions being postponed or confidence being dampened. Some of these effects might not be reversible.
• Clarification on Fiscal Situation: Darini clarifies that the "pre-measures forecast" showing a surplus did not account for welfare "u-turns" and the need to maintain headroom against financial markets, which necessitated revenue raising.
• NHS Spending on Medicines: The percentage of the NHS budget spent on medicines has decreased over the years (from 15% to 9%), which is lower than in Germany (15%) and France (14%).

Political Consequences:

• Shift in Focus: The OBR issue has overshadowed other political discussions, including the Prime Minister's planned remarks on the European Union, regulation, and welfare.
• Treasury Select Committee Hearing: Rachel Reeves is scheduled to appear before the Treasury Select Committee on Wednesday, December 10th, at 10:00 AM, to address these issues.
• Government's Internal Acknowledgment: While publicly defending their actions, senior figures within the government privately acknowledge that the process leading up to and following the budget has been "messy."

UK-US Deal on Drug Pricing

The podcast then transitions to a significant deal between the UK and the US concerning drug pricing.

Key Terms of the Deal:

• UK Benefit: The US will not apply import taxes (tariffs) on British-made pharmaceuticals for three years. This protects a key UK industry, worth £5 billion annually in exports to the US.
• UK Concessions:
  • The NHS will pay slightly more for pharmaceuticals.
  • The NHS will relax some rules regarding the assessment of new drugs' value for money.
• Specific Changes to NICE Thresholds:
  • The threshold for the cost per Quality-Adjusted Life Year (QALY) will increase from £20,000-£30,000 to £25,000-£35,000. This means more drugs are likely to be approved.
  • The rebate the NHS receives from drug companies will be capped at 15%, down from over 20% last year.

Background and Rationale:

• Trump Administration Tariffs: The issue arose when Donald Trump imposed tariffs on global imports, including pharmaceuticals, creating a threat to UK exports.
• US Argument: The US argued that European countries, including the UK, were paying significantly less for drugs, effectively subsidizing other nations.
• Pharmaceutical Industry Concerns: Drug companies were threatening to withdraw or pause investments in the UK due to slow approval processes and pricing disputes, impacting the UK's ambition to be a "life sciences superpower." Companies like AstraZeneca and Merck had already paused or cancelled projects.
• Negotiation Parties: The deal involved four parties: the NHS, the UK government, the pharmaceutical industry, and the US.
• Budget's Role: The UK budget was crucial in determining the NHS's spending capacity for new medicines, enabling the deal to be finalized.

Perspectives and Analysis:

• Government's View: The government argues that better medicines, properly applied, will keep people out of hospitals, thus paying for themselves. They also point out that the percentage of the NHS budget spent on medicines is lower than in other developed countries.
• Criticism: The Liberal Democrats have described the deal as a "Trump shakedown" of the NHS, implying the UK is paying more under duress.
• Tariff Outcome: The UK secured a 0% tariff, which is better than many expected, given the threats of higher tariffs from Trump.
• Investment Impact: The deal is hoped to stem the tide of investment withdrawal from drug companies and potentially encourage them to restart or reverse paused projects.
• Pull vs. Push Factors: The decision of drug companies to invest in the US versus the UK is seen as a combination of "pull" factors (US incentives) and "push" factors (UK policies making it less attractive). Simon Jack estimates a 70/30 split, with the push being a long-standing issue and the pull becoming more influential recently.
• Political Win: The deal is seen as a political win for the UK government, particularly for Chief Trade Negotiator Varun Chandra, who is considered a strong candidate for UK Ambassador to the US.

Conclusion

The episode highlights two major issues: the integrity of the budget process, marked by the OBR data breach and questions of transparency, and a significant international agreement on drug pricing that balances UK industry protection with NHS spending considerations. The resignation of the OBR head underscores the seriousness of the data breach, while the UK-US drug deal represents a complex negotiation with potential long-term economic and health implications. The podcast concludes by acknowledging that discussions around the budget and its fallout are likely to continue.